Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.

Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.

Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.

2.

SYK expression level distinguishes control from BRCA1-mutated lymphocytes.

Zahavi T, Sonnenblick A, Shimshon Y, Kadouri L, Peretz T, Salmon AY, Salmon-Divon M.

Cancer Manag Res. 2018 Mar 26;10:589-598. doi: 10.2147/CMAR.S156359. eCollection 2018.

3.

Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy.

Grinshpun A, Gavert N, Granit RZ, Masuri H, Ben-Porath I, Breuer S, Zick A, Rosenberg S, Maoz M, Granit A, Pikarsky E, Strausmman R, Peretz T, Sonnenblick A.

Cancer Biol Ther. 2018 Mar 22:1-4. doi: 10.1080/15384047.2018.1450114. [Epub ahead of print]

PMID:
29565707
4.

Breast cancer among older women: The influence of age and cancer stage on survival.

Rottenberg Y, Naeim A, Uziely B, Peretz T, Jacobs JM.

Arch Gerontol Geriatr. 2018 May - Jun;76:60-64. doi: 10.1016/j.archger.2018.02.004. Epub 2018 Feb 13.

PMID:
29459246
5.

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.

Purim O, Beny A, Inbar M, Shulman K, Brenner B, Dudnik E, Bokstein F, Temper M, Limon D, Matceyevsky D, Sarid D, Segal A, Semenisty V, Brenner R, Peretz T, Idelevich E, Pelles-Avraham S, Meirovitz A, Figer A, Russell K, Voss A, Dvir A, Soussan-Gutman L, Hubert A.

Target Oncol. 2018 Apr;13(2):217-226. doi: 10.1007/s11523-017-0548-8.

6.

Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.

Grinshpun A, Halpern N, Granit RZ, Hubert A, Hamburger T, Laitman Y, Shacham-Shmueli E, Peerless Y, Friedman E, Peretz T.

Eur J Hum Genet. 2018 Mar;26(3):382-386. doi: 10.1038/s41431-017-0067-1. Epub 2018 Jan 10.

PMID:
29321669
7.

BRCA mutations and reproduction.

Daum H, Peretz T, Laufer N.

Fertil Steril. 2018 Jan;109(1):33-38. doi: 10.1016/j.fertnstert.2017.12.004. Review.

PMID:
29307397
8.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, Peretz T, Lotem M.

Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.

PMID:
29305520
9.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, De Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C.

Int J Oncol. 2018 Feb;52(2):424-432. doi: 10.3892/ijo.2017.4212. Epub 2017 Nov 27.

PMID:
29207087
10.

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, McCullough D, Svedman C, Shak S, Liebermann N, Ben-Baruch N.

NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017.

11.

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.

Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H.

Medicine (Baltimore). 2017 May;96(20):e6931. doi: 10.1097/MD.0000000000006931.

12.

Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.

Halpern N, Goldberg Y, Kadouri L, Duvdevani M, Hamburger T, Peretz T, Hubert A.

Onco Targets Ther. 2017 Mar 29;10:1889-1896. doi: 10.2147/OTT.S126905. eCollection 2017.

13.

Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.

Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts BH, Pritchard CC, Tomlinson I, King MC, Levy-Lahad E, Peretz T, Goldberg Y.

Gastroenterology. 2017 Jun;152(8):1876-1880.e1. doi: 10.1053/j.gastro.2017.02.014. Epub 2017 Feb 24.

PMID:
28242209
14.

Exclusive destruction of mitotic spindles in human cancer cells.

Visochek L, Castiel A, Mittelman L, Elkin M, Atias D, Golan T, Izraeli S, Peretz T, Cohen-Armon M.

Oncotarget. 2017 Mar 28;8(13):20813-20824. doi: 10.18632/oncotarget.15343.

15.

Adoptive cell therapy: past, present and future.

Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M.

Immunotherapy. 2017 Jan;9(2):183-196. doi: 10.2217/imt-2016-0112. Review.

PMID:
28128715
16.

Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.

Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, Peretz T, Kadouri L.

Int J Cancer. 2017 May 1;140(9):2145-2149. doi: 10.1002/ijc.30616. Epub 2017 Feb 8.

17.

Heparanase augments insulin receptor signaling in breast carcinoma.

Goldberg R, Sonnenblick A, Hermano E, Hamburger T, Meirovitz A, Peretz T, Elkin M.

Oncotarget. 2017 Mar 21;8(12):19403-19412. doi: 10.18632/oncotarget.14292.

18.

Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40.

Levin N, Pato A, Cafri G, Eisenberg G, Peretz T, Margalit A, Lotem M, Gross G.

J Immunother. 2017 Feb/Mar;40(2):39-50. doi: 10.1097/CJI.0000000000000150.

PMID:
28005579
19.

Erratum to: Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer.

Jaber M, Maoz M, Kancharla A, Agranovich D, Peretz T, Grisaru-Granovsky S, Uziely B, Bar-Shavit R.

Cell Mol Life Sci. 2017 Feb;74(3):571-577. doi: 10.1007/s00018-016-2424-6. No abstract available.

PMID:
27900391
20.

Recurrent TP53 missense mutation in cancer patients of Arab descent.

Zick A, Kadouri L, Cohen S, Frohlinger M, Hamburger T, Zvi N, Plaser M, Avital E, Breuier S, Elian F, Salah A, Goldberg Y, Peretz T.

Fam Cancer. 2017 Apr;16(2):295-301. doi: 10.1007/s10689-016-9951-z.

PMID:
27866339
21.

Double-Edged Sword: Women with Breast Cancer Caring for a Spouse with Cancer.

Rottenberg Y, Baider L, Jacobs JM, Peretz T, Goldzweig G.

J Womens Health (Larchmt). 2016 Dec;25(12):1270-1275. Epub 2016 Oct 6.

PMID:
27710181
22.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
23.

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.

Katz D, Azraq Y, Eleyan F, Gill S, Peretz T, Merimsky O.

BMC Cancer. 2016 Aug 8;16:616. doi: 10.1186/s12885-016-2618-1.

24.

The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.

Gross M, Meirovich A, Rachmut J, Kalichman I, Peretz T, Eliashar R, Barak V.

Anticancer Res. 2016 Aug;36(8):4347-52.

PMID:
27466555
25.

Feasibility of Unbiased RNA Profiling of Colorectal Tumors: A Proof of Principle.

Moshayoff V, Faktor O, Laghi L, Celesti G, Peretz T, Keret D, Cohen D, Israeli E.

PLoS One. 2016 Jul 21;11(7):e0159522. doi: 10.1371/journal.pone.0159522. eCollection 2016.

26.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

27.

Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.

Nisman B, Appelbaum L, Yutkin V, Nechushtan H, Hubert A, Uziely B, Pode D, Peretz T.

Anticancer Res. 2016 Apr;36(4):1791-7.

PMID:
27069161
28.

Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants.

Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, Peretz T, Margalit A, Lotem M, Gross G.

J Immunother. 2016 Feb-Mar;39(2):60-70. doi: 10.1097/CJI.0000000000000109.

PMID:
26849075
29.

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.

Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar J, Onn A, Uziely B, Peretz T.

Br J Cancer. 2016 Feb 16;114(4):469-76. doi: 10.1038/bjc.2016.7. Epub 2016 Jan 26.

30.

Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.

Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A.

Oncotarget. 2016 Jan 26;7(4):4860-70. doi: 10.18632/oncotarget.6638.

31.
32.

Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β.

Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S.

Anticancer Res. 2015 Dec;35(12):6755-60.

PMID:
26637892
33.

PH motifs in PAR1&2 endow breast cancer growth.

Kancharla A, Maoz M, Jaber M, Agranovich D, Peretz T, Grisaru-Granovsky S, Uziely B, Bar-Shavit R.

Nat Commun. 2015 Nov 24;6:8853. doi: 10.1038/ncomms9853.

34.

Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.

Baris HN, Barnes-Kedar I, Toledano H, Halpern M, Hershkovitz D, Lossos A, Lerer I, Peretz T, Kariv R, Cohen S, Half EE, Magal N, Drasinover V, Wimmer K, Goldberg Y, Bercovich D, Levi Z.

Pediatr Blood Cancer. 2016 Mar;63(3):418-27. doi: 10.1002/pbc.25818. Epub 2015 Nov 6.

PMID:
26544533
35.

Unemployment risk and income change after testicular cancer diagnosis: A population-based study.

Rottenberg Y, Ratzon NZ, Jacobs JM, Cohen M, Peretz T, de Boer AG.

Urol Oncol. 2016 Jan;34(1):5.e27-33. doi: 10.1016/j.urolonc.2015.08.016. Epub 2015 Oct 1.

PMID:
26427695
36.

The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.

Barak V, Meirovitz A, Leibovici V, Rachmut J, Peretz T, Eliashar R, Gross M.

Anticancer Res. 2015 Oct;35(10):5519-24.

PMID:
26408719
37.

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, Merims S, Peretz T, Lotem M, Gross G.

Clin Exp Immunol. 2015 Nov;182(2):220-9. doi: 10.1111/cei.12688. Epub 2015 Aug 28.

38.

Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.

Sonnenblick A, Eleyan F, Peretz T, Ospovat I, Merimsky O, Sella T, Peylan-Ramu N, Katz D.

Mol Clin Oncol. 2015 Jul;3(4):829-832. Epub 2015 Apr 16.

39.

Is (18)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?

Orevi M, Freedman N, Tahover E, Uziely B, Chisin R, Peretz T, Klein M.

Acta Oncol. 2016;55(2):244-7. doi: 10.3109/0284186X.2015.1054952. Epub 2015 Jun 24. No abstract available.

PMID:
26106853
40.

Characterization of tumor infiltrating natural killer cell subset.

Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J.

Oncotarget. 2015 May 30;6(15):13835-43.

41.

A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.

Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, Nisman B, Peretz T, Peylan-Ramu N.

Oncologist. 2015 Apr;20(4):366-7. doi: 10.1634/theoncologist.2014-0424. Epub 2015 Mar 16.

42.

Human T cell crosstalk is induced by tumor membrane transfer.

Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, Engelstein R, Peretz T, Machlenkin A, Lotem M.

PLoS One. 2015 Feb 11;10(2):e0118244. doi: 10.1371/journal.pone.0118244. eCollection 2015.

43.

Expectations and Level of Satisfaction of Patients and Their Physicians: Concordance and Discrepancies.

Goldzweig G, Abramovitch A, Brenner B, Perry S, Peretz T, Baider L.

Psychosomatics. 2015 Sep-Oct;56(5):521-9. doi: 10.1016/j.psym.2014.10.001. Epub 2014 Oct 5.

PMID:
25596021
44.

Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.

Nisman B, Nechushtan H, Biran H, Gantz-Sorotsky H, Peled N, Gronowitz S, Peretz T.

J Thorac Oncol. 2014 Oct;9(10):1568-72. doi: 10.1097/JTO.0000000000000276.

45.

Genetic features of Lynch syndrome in the Israeli population.

Goldberg Y, Barnes-Kedar I, Lerer I, Halpern N, Plesser M, Hubert A, Kadouri L, Goldshmidt H, Solar I, Strul H, Rosner G, Baris HN, Peretz T, Levi Z, Kariv R.

Clin Genet. 2015 Jun;87(6):549-53. doi: 10.1111/cge.12530. Epub 2014 Nov 28.

PMID:
25430799
46.

Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme.

Hermano E, Meirovitz A, Meir K, Nussbaum G, Appelbaum L, Peretz T, Elkin M.

J Natl Cancer Inst. 2014 Oct 18;106(12). pii: dju332. doi: 10.1093/jnci/dju332. Print 2014 Dec.

47.

Silent Partners to Cancer Patients: Formal Caregivers and Oncologists.

Goldzweig G, Rottenberg Y, Peretz T, Baider L.

J Cancer Educ. 2015 Dec;30(4):704-10. doi: 10.1007/s13187-014-0741-8.

PMID:
25316613
48.

The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort.

Grenader T, Yerushalmi R, Tokar M, Fried G, Kaufman B, Peretz T, Geffen DB.

Oncology. 2014;87(1):1-6. doi: 10.1159/000360793. Epub 2014 Jun 20.

PMID:
24970679
49.

A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients.

Nechushtan H, Vainer G, Stainberg H, Salmon AY, Hamburger T, Peretz T.

Breast. 2014 Aug;23(4):435-8. doi: 10.1016/j.breast.2014.03.003. Epub 2014 May 14.

PMID:
24836394
50.

An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.

Tahover E, Hubert A, Temper M, Salah A, Peretz T, Hamburger T, Uziely B.

Target Oncol. 2015 Mar;10(1):55-63. doi: 10.1007/s11523-014-0311-3. Epub 2014 Mar 6.

PMID:
24599713

Supplemental Content

Loading ...
Support Center